<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d248" origId="Gefitinib"><sentence id="DrugDDI.d248.s0" origId="s0" text="Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations."><entity charOffset="32-38" id="DrugDDI.d248.s0.e0" origId="s0.p4" text="CYP3A4" type="drug"/><entity charOffset="75-84" id="DrugDDI.d248.s0.e1" origId="s0.p7" text="gefitinib" type="drug"/><pair e1="DrugDDI.d248.s0.e0" e2="DrugDDI.d248.s0.e1" id="DrugDDI.d248.s0.p0" interaction="false"/></sentence><sentence id="DrugDDI.d248.s1" origId="s1" text="In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections)."><entity charOffset="31-37" id="DrugDDI.d248.s1.e0" origId="s1.p13" text="CYP3A4" type="drug"/><entity charOffset="54-64" id="DrugDDI.d248.s1.e1" origId="s1.p14" text="rifampicin" type="drug"/><entity charOffset="68-77" id="DrugDDI.d248.s1.e2" origId="s1.p16" text="phenytoin" type="drug"/><pair e1="DrugDDI.d248.s1.e0" e2="DrugDDI.d248.s1.e1" id="DrugDDI.d248.s1.p0" interaction="false"/><pair e1="DrugDDI.d248.s1.e0" e2="DrugDDI.d248.s1.e2" id="DrugDDI.d248.s1.p1" interaction="false"/><pair e1="DrugDDI.d248.s1.e1" e2="DrugDDI.d248.s1.e2" id="DrugDDI.d248.s1.p2" interaction="false"/><negationtags>In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the &lt;xcope&gt;&lt;cue&gt;absence&lt;/cue&gt; of severe adverse drug reaction&lt;/xcope&gt;, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).</negationtags></sentence><sentence id="DrugDDI.d248.s2" origId="s2" text="International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy."><entity charOffset="114-122" id="DrugDDI.d248.s2.e0" origId="s2.p52" text="warfarin" type="drug"/><entity charOffset="132-138" id="DrugDDI.d248.s2.e1" origId="s2.p54" text="IRESSA" type="drug"/><pair e1="DrugDDI.d248.s2.e0" e2="DrugDDI.d248.s2.e1" id="DrugDDI.d248.s2.p0" interaction="true"/></sentence><sentence id="DrugDDI.d248.s3" origId="s3" text="Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR."><entity charOffset="16-24" id="DrugDDI.d248.s3.e0" origId="s3.p57" text="warfarin" type="drug"/></sentence><sentence id="DrugDDI.d248.s4" origId="s4" text="Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations."><entity charOffset="41-47" id="DrugDDI.d248.s4.e0" origId="s4.p70" text="CYP3A4" type="drug"/><entity charOffset="62-74" id="DrugDDI.d248.s4.e1" origId="s4.p73" text="ketoconazole" type="drug"/><entity charOffset="79-91" id="DrugDDI.d248.s4.e2" origId="s4.p75" text="itraconazole" type="drug"/><entity charOffset="102-111" id="DrugDDI.d248.s4.e3" origId="s4.p78" text="gefitinib" type="drug"/><entity charOffset="136-145" id="DrugDDI.d248.s4.e4" origId="s4.p80" text="gefitinib" type="drug"/><pair e1="DrugDDI.d248.s4.e0" e2="DrugDDI.d248.s4.e1" id="DrugDDI.d248.s4.p0" interaction="false"/><pair e1="DrugDDI.d248.s4.e0" e2="DrugDDI.d248.s4.e2" id="DrugDDI.d248.s4.p1" interaction="false"/><pair e1="DrugDDI.d248.s4.e0" e2="DrugDDI.d248.s4.e3" id="DrugDDI.d248.s4.p2" interaction="false"/><pair e1="DrugDDI.d248.s4.e0" e2="DrugDDI.d248.s4.e4" id="DrugDDI.d248.s4.p3" interaction="false"/><pair e1="DrugDDI.d248.s4.e1" e2="DrugDDI.d248.s4.e2" id="DrugDDI.d248.s4.p4" interaction="false"/><pair e1="DrugDDI.d248.s4.e1" e2="DrugDDI.d248.s4.e3" id="DrugDDI.d248.s4.p5" interaction="true"/><pair e1="DrugDDI.d248.s4.e1" e2="DrugDDI.d248.s4.e4" id="DrugDDI.d248.s4.p6" interaction="false"/><pair e1="DrugDDI.d248.s4.e2" e2="DrugDDI.d248.s4.e3" id="DrugDDI.d248.s4.p7" interaction="true"/><pair e1="DrugDDI.d248.s4.e2" e2="DrugDDI.d248.s4.e4" id="DrugDDI.d248.s4.p8" interaction="false"/><pair e1="DrugDDI.d248.s4.e3" e2="DrugDDI.d248.s4.e4" id="DrugDDI.d248.s4.p9" interaction="false"/></sentence><sentence id="DrugDDI.d248.s5" origId="s5" text="This increase may be clinically relevant as adverse experiences are related to dose and exposure;"/><sentence id="DrugDDI.d248.s6" origId="s6" text="therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA."><entity charOffset="53-59" id="DrugDDI.d248.s6.e0" origId="s6.p98" text="CYP3A4" type="drug"/><entity charOffset="76-82" id="DrugDDI.d248.s6.e1" origId="s6.p99" text="IRESSA" type="drug"/><pair e1="DrugDDI.d248.s6.e0" e2="DrugDDI.d248.s6.e1" id="DrugDDI.d248.s6.p0" interaction="false"/></sentence><sentence id="DrugDDI.d248.s7" origId="s7" text="Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy."><entity charOffset="0-5" id="DrugDDI.d248.s7.e0" origId="s7.p100" text="Drugs" type="drug"/><entity charOffset="64-97" id="DrugDDI.d248.s7.e1" origId="s7.p106" text="histamine h2-receptor antagonists" type="drug"/><entity charOffset="106-116" id="DrugDDI.d248.s7.e2" origId="s7.p107" text="ranitidine" type="drug"/><entity charOffset="120-130" id="DrugDDI.d248.s7.e3" origId="s7.p109" text="cimetidine" type="drug"/><entity charOffset="168-174" id="DrugDDI.d248.s7.e4" origId="s7.p114" text="IRESSA" type="drug"/><pair e1="DrugDDI.d248.s7.e0" e2="DrugDDI.d248.s7.e1" id="DrugDDI.d248.s7.p0" interaction="false"/><pair e1="DrugDDI.d248.s7.e0" e2="DrugDDI.d248.s7.e2" id="DrugDDI.d248.s7.p1" interaction="false"/><pair e1="DrugDDI.d248.s7.e0" e2="DrugDDI.d248.s7.e3" id="DrugDDI.d248.s7.p2" interaction="false"/><pair e1="DrugDDI.d248.s7.e0" e2="DrugDDI.d248.s7.e4" id="DrugDDI.d248.s7.p3" interaction="true"/><pair e1="DrugDDI.d248.s7.e1" e2="DrugDDI.d248.s7.e2" id="DrugDDI.d248.s7.p4" interaction="false"/><pair e1="DrugDDI.d248.s7.e1" e2="DrugDDI.d248.s7.e3" id="DrugDDI.d248.s7.p5" interaction="false"/><pair e1="DrugDDI.d248.s7.e1" e2="DrugDDI.d248.s7.e4" id="DrugDDI.d248.s7.p6" interaction="false"/><pair e1="DrugDDI.d248.s7.e2" e2="DrugDDI.d248.s7.e3" id="DrugDDI.d248.s7.p7" interaction="false"/><pair e1="DrugDDI.d248.s7.e2" e2="DrugDDI.d248.s7.e4" id="DrugDDI.d248.s7.p8" interaction="true"/><pair e1="DrugDDI.d248.s7.e3" e2="DrugDDI.d248.s7.e4" id="DrugDDI.d248.s7.p9" interaction="false"/></sentence><sentence id="DrugDDI.d248.s8" origId="s8" text="Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine."><entity charOffset="36-42" id="DrugDDI.d248.s8.e0" origId="s8.p121" text="IRESSA" type="drug"/><entity charOffset="47-58" id="DrugDDI.d248.s8.e1" origId="s8.p123" text="vinorelbine" type="drug"/><entity charOffset="103-109" id="DrugDDI.d248.s8.e2" origId="s8.p129" text="IRESSA" type="drug"/><entity charOffset="151-162" id="DrugDDI.d248.s8.e3" origId="s8.p133" text="vinorelbine" type="drug"/><pair e1="DrugDDI.d248.s8.e0" e2="DrugDDI.d248.s8.e1" id="DrugDDI.d248.s8.p0" interaction="false"/><pair e1="DrugDDI.d248.s8.e0" e2="DrugDDI.d248.s8.e2" id="DrugDDI.d248.s8.p1" interaction="false"/><pair e1="DrugDDI.d248.s8.e0" e2="DrugDDI.d248.s8.e3" id="DrugDDI.d248.s8.p2" interaction="false"/><pair e1="DrugDDI.d248.s8.e1" e2="DrugDDI.d248.s8.e2" id="DrugDDI.d248.s8.p3" interaction="false"/><pair e1="DrugDDI.d248.s8.e1" e2="DrugDDI.d248.s8.e3" id="DrugDDI.d248.s8.p4" interaction="false"/><pair e1="DrugDDI.d248.s8.e2" e2="DrugDDI.d248.s8.e3" id="DrugDDI.d248.s8.p5" interaction="true"/></sentence></document>